Progestin alone as primary treatment of endometrial carcinoma in premenopausal women

Kim, Young B.; Holschneider, Christine H.; Ghosh, Kris; Nieberg, Roberta K.; Montz, F.J.

doi:10.1002/(sici)1097-0142(19970115)79:2<320::aid-cncr15>3.0.co;2-2

Cited by 249 publications

(152 citation statements)

References 27 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Some small series have been reported in which grade 1, stage 1 ECs have been successfully treated with progestins alone (for reviews see Kim et al 1997, Randall & Kurman 1997, Quinn 1999. A response rate of 66% has been calculated and 11 pregnancies (two after in vitro fertilization) have been reported (Paulson et al 1990, Kim et al 1997, Randall & Kurman 1997, Zuckerman et al 1998.…”

Section: Primary Treatment Of Early Ec With Progestinsmentioning

confidence: 99%

Hormonal interactions in endometrial cancer.

Emons

Fleckenstein

Hinney³

et al. 2000

Endocrine-Related Cancer

172

129

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most frequent malignant tumor of the female genital tract. Increasing evidence suggests that at least two different types of EC exist. Type I is associated with an endocrine milieu of estrogen predominance. These tumors are of endometrioid histology and develop from endometrial hyperplasia. They have a good prognosis and are sensitive to endocrine manipulation. Type II EC is not associated with a history of unopposed estrogens and develops from the atrophic endometrium of elderly women. They are of serous histology, have a poor prognosis, and do not react to endocrine manipulation. Both types of EC probably differ markedly with regard to the molecular mechanisms of malignant transformation. This article reviews reproductive and lifestyle factors modifying the risk of developing type I EC, including the use of hormonal contraceptives, hormone replacement therapy and tamoxifen. The roles of established and novel therapies for precancerous lesions and for invasive EC in the adjuvant and palliative settings are discussed.

show abstract

Section: Primary Treatment Of Early Ec With Progestinsmentioning

confidence: 99%

Hormonal interactions in endometrial cancer.

Emons

Fleckenstein

Hinney³

et al. 2000

Endocrine-Related Cancer

172

129

View full text Add to dashboard Cite

show abstract

“…Studies at various institutions have reported the results of fertility-sparing treatment for EC using progesterone preparations (8)(9)(10)(11)(12)(13)(14)(15)(16)(17). However, as the number of cases have been low, the efficacy of such treatment has yet to be clarified.…”

Section: Introductionmentioning

confidence: 99%

Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. The purpose of this study was to present the results of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC), and to clarify patient characteristics by investigating patient background factors. A total of 59 patients with EC, who received MPA as fertility-sparing therapy at two institutions over a 21-year period between 1987 and 2008, were studied retrospectively. Patients were administered oral MPA at 400-600 mg/day for 16-24 weeks as long as they responded. Endometrial tissue was assessed twice, at 8-12 weeks (during treatment) and shortly after treatment. The overall complete response (CR) rate was 71%. A total of 22 (52%) of 42 responders later developed relapse. A total of 19 cases became pregnant, and 25 infants were born. Eighty percent of recurrences occurred within 2 years. For stages Ⅰa and Ⅰb-Ⅱa (FIGO, 1988), initial CR rates were 80.0 and 42.9%, respectively (p<0.01), demonstrating a significant difference. Total hysterectomy was performed for 26 patients (44%) due to recurrence or failure to respond to the initial treatment. Among these 26 patients, postoperative stages were more advanced in 10 patients (38%). The grade advanced (became more poorly differentiated) postoperatively in 2 patients (8%). Premenopausal females with EC can be treated successfully with MPA, however patients should be informed of the risks and limitations of this conservative treatment. IntroductionIn Western countries, endometrial carcinoma (EC) is the most common type of malignant tumor in the field of gynecology (1,2). A state of persistent high estrogen, as observed with ovulation disorders and obesity, is considered a risk factor (3-5). The standard treatments for EC are total hysterectomy and bilateral adnexectomy.EC is a disease that frequently affects perimenopausal females, however approximately 10% of affected females are ≤40 years old, and the incidence in young females has recently been on the increase (6). As in Western countries, the number of ≤40-year-old females with EC in Japan is on the rise (7). Thus, the number of patients who select to undergo fertilitysparing treatment is growing.Studies at various institutions have reported the results of fertility-sparing treatment for EC using progesterone preparations (8-17). However, as the number of cases have been low, the efficacy of such treatment has yet to be clarified. Furthermore, few studies have closely described the clinical background of young females with early-stage EC wishing to undergo fertility-sparing treatment.The present study investigated the effects of treatment, prognosis, pregnancy status and other factors, in order to demonstrate the therapeutic outcomes of current fertility-sparing treatment. Furthermore, patient background factors were investigated to elucidate the characteristics of the patient group. Patients and methods Patients.A total of 59 patients with EC who underwent fertilitysparing treatment, at either the Jichi Medical University Hospital or the Kitasato University Hospit...

show abstract

“…To summarize the domestic and overseas reports on progestin therapy applied as fertility-preserving therapy in 1997 through 2008, the lesions disappeared in 164 (75%) of the 218 cases of endometrial cancer (corresponding to G1 endometrioid adenocarcinoma, FIGO 1988 surgical stage Ia) in response to progestin therapy. Among these 164 cases showing disappearance of lesions, recurrence was later noted in 53 (36%) of the 148 cases where information on the presence/absence of recurrence was available (Table I) (14,(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). When progestin therapy was applied to 47 cases of atypical endometrial hyperplasia, 42 cases (89%) showed disappearance of lesions, and 8 (19%) of these 42 cases later showed recurrence (Table II) (26,27,31,35).…”

Section: Progestin Therapy For Endometrial Cancermentioning

confidence: 99%

“…Among these 164 cases showing disappearance of lesions, recurrence was later noted in 53 (36%) of the 148 cases where information on the presence/absence of recurrence was available (Table I) (14,(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). When progestin therapy was applied to 47 cases of atypical endometrial hyperplasia, 42 cases (89%) showed disappearance of lesions, and 8 (19%) of these 42 cases later showed recurrence (Table II) (26,27,31,35). Regarding the efficacy of progestin therapy on endometrial cancer, Montz et al reported that when progestin therapy was administered to cases of G1 endometrial cancer (FIGO 1988 surgical stage Ia) not indicated for surgery for reasons of influence of complications or preservation of fertility, the tumor was histologically rated as negative in 7 of the 11 cases at 6 months and 6 of the 8 cases at 12 months after the start of treatment (36).…”

Section: Progestin Therapy For Endometrial Cancermentioning

confidence: 99%

Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)

et al. 2012

View full text Add to dashboard Cite

Abstract. Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer. Contents

show abstract

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women

Abstract: The results of this study show that premenopausal women with endometrial carcinoma may be treated successfully with progestin therapy alone as primary therapy to preserve childbearing potential.

Cited by 249 publications

References 27 publications

Hormonal interactions in endometrial cancer.

Hormonal interactions in endometrial cancer.

Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma

Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)

Contact Info

Product

Resources

About